Acorn Capital Advisors, LLC

In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Acorn Capital Advisors, LLC reported 22 stock positions worth $351.8 million. Its top holding was Terns Pharmaceuticals (TERN) at 26.2% of the portfolio, followed by CG Oncology (CGON, 21.8%) and Urogen Pharma (URGN, 8.6%). Compared with Q4 2025, it opened 2 new positions, sold out of 1, added to 4 and reduced 6. The biggest buy was a new position in Jade Biosciences (JBIO) and the biggest sale Cybin (HELP, shares −2%).

Most Recent 13F
Q2 2026
Location
NEW YORK, NY
CIK
0002054410
Portfolio Value
$351.8M (Q1 2026)
SEC Filing
0001636587-26-000029 ↗ filed May 15, 2026

Holdings Value

0$100.0M$200.0M$300.0M$400.0M Q4 2024: $185.8M Q4 2024 Q1 2025: $149.9M Q1 2025 Q2 2025: $152.9M Q2 2025 Q3 2025: $197.0M Q3 2025 Q4 2025: $295.1M Q4 2025 Q1 2026: $351.8M $351.8M Q1 2026 Q2 2026: $366.5M Q2 2026

Holdings 22 stocks · $351.8M
TERN Terns Pharmaceuticals Inc. 26.17% 1,746,264 $92.1M No change
CGON CG Oncology Inc. 21.77% 1,130,501 $76.6M Reduce -0.1%
URGN Urogen Pharma Ltd. 8.55% 1,673,420 $30.1M Add +15.5%
PBYI Puma Biotechnology Inc. 7.50% 4,131,299 $26.4M No change
TRVI Trevi Therapeutics Inc. 7.27% 2,144,844 $25.6M No change
CADL Candel Therapeutics Inc. 4.89% 3,497,948 $17.2M Add +35.5%
BCAX Bicara Therapeutics Inc. 3.64% 643,382 $12.8M No change
OKUR Onkure Therapeutics Inc. Class A 3.34% 2,839,674 $11.8M No change
JBIO Jade Biosciences Inc. 3.14% 786,760 $11.1M New
TARA Protara Therapeutic Inc. 2.59% 1,752,115 $9.1M No change
VSTM Verastem Inc. 2.21% 1,469,153 $7.8M No change
HELP Cybin Inc. 2.10% 1,540,266 $7.4M Reduce -2.1%
LONA Leonabio Inc. 1.85% 634,539 $6.5M Add +26.5%
AURA Aura Biosciences Inc. 1.13% 595,744 $4.0M No change
WHWK Whitehawk Therapeutics Inc. 1.12% 1,139,363 $3.9M No change
CRDF Cardiff Oncology Inc. 0.81% 1,762,084 $2.9M Reduce -10.2%
QTTB Q32 Bio Inc. 0.57% 315,052 $2.0M Reduce -36.1%
KPTI Karyopharm Therapeutics Inc. 0.46% 287,826 $1.6M New
JSPR Jasper Therapeutics Inc. 0.35% 1,411,492 $1.2M Reduce -21.0%
XFOR X4 Pharmaceuticals Inc. 0.27% 234,039 $967K Reduce -14.4%
BCAB Bioatla Inc. 0.25% 5,406,345 $865K Add +11.8%
VYNE THERAPEUTICS INC 0.00% 1,425 $855 No change

Portfolio Sells Q4 2025 → Q1 2026
HELP Cybin Inc. Reduce -2.1% 2.10% −2.26
CRDF Cardiff Oncology Inc. Reduce -10.2% 0.81% −1.06
JSPR Jasper Therapeutics Inc. Reduce -21.0% 0.35% −0.75
ACRV Acrivon Therapeutics Inc. Sold out 0.00% −0.33
XFOR X4 Pharmaceuticals Inc. Reduce -14.4% 0.27% −0.10
QTTB Q32 Bio Inc. Reduce -36.1% 0.57% +0.02
CGON CG Oncology Inc. Reduce -0.1% 21.77% +5.85

Portfolio Buys Q4 2025 → Q1 2026
JBIO Jade Biosciences Inc. New 3.14% +3.14
LONA Leonabio Inc. Add +26.5% 1.85% +0.57
KPTI Karyopharm Therapeutics Inc. New 0.46% +0.46
CADL Candel Therapeutics Inc. Add +35.5% 4.89% −0.05
BCAB Bioatla Inc. Add +11.8% 0.25% −0.69
URGN Urogen Pharma Ltd. Add +15.5% 8.55% −2.94

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 20$366.5MCGON, URGN, TRVI, CADL, PBYI
Q1 2026 22$351.8MTERN, CGON, URGN, PBYI, TRVI
Q4 2025 21$295.1MTERN, CGON, URGN, TRVI, PBYI
Q3 2025 20$197.0MCGON, URGN, PBYI, TRVI, TERN
Q2 2025 21$152.9MCGON, URGN, YMAB, PBYI, CADL
Q1 2025Amended 22$149.9MCGON, URGN, YMAB, TRVI, CADL
Q4 2024Amended 21$185.8MCGON, YMAB, CADL, URGN, PBYI